From Morphological Imaging to Molecular Targeting(English, Hardcover, unknown)

From Morphological Imaging to Molecular Targeting(English, Hardcover, unknown)

  • unknown
Publisher:Springer Science & Business MediaISBN 13: 9783540201373ISBN 10: 3540201378

Paperback & Hardcover deals ―

Amazon IndiaGOFlipkart ₹ 17394SnapdealGOSapnaOnlineGOJain Book AgencyGOBooks Wagon₹5,171Book ChorGOCrosswordGODC BooksGO

e-book & Audiobook deals ―

Amazon India GOGoogle Play Books GOAudible GO

* Price may vary from time to time.

* GO = We're not able to fetch the price (please check manually visiting the website).

Know about the book -

From Morphological Imaging to Molecular Targeting(English, Hardcover, unknown) is written by unknown and published by Springer-Verlag Berlin and Heidelberg GmbH & Co. KG. It's available with International Standard Book Number or ISBN identification 3540201378 (ISBN 10) and 9783540201373 (ISBN 13).

Because of the current progress in molecular medicine (genomics, proteomics), a plethora of new and often human-specific targets are being identified. These targets often play a significant role in the pathogenesis of diseases, and identifying them offers the potential for early diagnosis and intervention. An early in vivo validation of specific ligands binding to these targets in humans is needed to as- sess their potential for targeted imaging and radiotherapy. Further- VI Preface more, such validation studies may allow for a better understanding of the molecular processes underlying phannacologic activity and therefore for a more successful development of phannaceuticals in general. The purpose of the Ernst Schering Research Foundation (ESRF) Workshop 48 was to provide a forum for an open exchange on the state of the art in the early development of such radiophanna- ceuticals. Experts from academia, industry, and regulatory authori- ties were invited to give presentations on aspects covering the identi- fication of targets, preclinical studies on the safety of ligands, as well as their validation in human clinical trials.It was our intention to cover both the opportunities and the challenges that scientists in this field are facing. Radiopharmaceuticals are uniquely suitable for the above-men- tioned target validation studies.